Navigation Links
Nektar to Announce Financial Results for the Fourth Quarter and Year-End of 2010 on Tuesday, March 1, 2011, After Close of U.S.-Based Financial Markets
Date:2/17/2011

SAN FRANCISCO, Feb. 17, 2011 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the fourth quarter ended December 31, 2010 on Tuesday, March 1, 2011, after the close of U.S.-based financial markets. Howard Robin, president and chief executive officer, will host a conference call to review the results beginning at 5:00 p.m. Eastern Time (ET)/2:00 p.m. Pacific Time (PT).

The press release and a live audio-only webcast of the conference call can be accessed through a link that is posted on the home page and Investor Relations section of the Nektar website: http://www.nektar.com. The web broadcast of the conference call will be available for replay through Tuesday, March 29, 2011. To access the conference call, follow these instructions:Dial: (866) 713-8307 (U.S.); (617) 597-5307 (international)Passcode: 79375407 (Nektar Therapeutics is the host)An audio replay will also be available shortly following the call through Tuesday, March 29, 2011 and can be accessed by dialing (888) 286-8010 (U.S.); or (617) 801-6888 (international) with a passcode of 10590598.

In the event that any non-GAAP financial measure is discussed on the conference call that is not described in the press release, or explained on the conference call, related information will be made available on the Investor Relations page at the Nektar website as soon as practical after the conclusion of the conference call.

About NektarNektar Therapeutics is a biopharmaceutical company developing novel therapeutics based on its PEGylation and advanced polymer conjugation technology platforms. Nektar has a robust R&D pipeline of potentially high-value therapeutics in oncology, pain and other areas. In the area of pain, Nektar has an exclusive worldwide license agreement with AstraZeneca for Nektar's oral NKTR-118 late-stage deve
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Nektar Commences Phase 2 Clinical Development Program for NKTR-102 (PEG-Irinotecan) in Colorectal Cancer
2. Nektar Commences Phase 2 Trial of NKTR-118 (oral PEG-naloxol) Evaluating Efficacy and Safety as Treatment for Opioid-Induced Bowel Dysfunction
3. Nektar Terminates All Negotiations With Potential Partners for Inhaled Insulin; Increased Number of Lung Cancer Cases Observed in Ongoing Clinical Studies of Inhaled Insulin Patients
4. Nektar Therapeutics to Present Positive Data at Upcoming Medical and Scientific Meetings
5. Nektar to Webcast Presentation of Phase 1 Clinical Results for Lead Small Molecule PEG-Oncolytic Program, NKTR-102 (PEG-irinotecan)
6. Nektar Announces Expanded Phase 2 Clinical Development Plan For NKTR-102 (PEG-irinotecan)
7. Nektar Announces Positive Results from Phase 2 Study of Oral NKTR-118 in Patients with Opioid-Induced Constipation (OIC)
8. Nektar Therapeutics Reports Second Quarter 2009 Financial Results
9. Nektar Presents Data Demonstrating Favorable Oral Bioavailability and Drug-Drug Interaction Profile for NKTR-118
10. Nektar Therapeutics Promotes Lorianne Masuoka, M.D. to Senior Vice President and Chief Medical Officer
11. Nektar Presents New Preclinical Data on NKTR-181 at Anesthesiology 2010
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... According to a new market research report ... Ablation Catheter (Cryoablation, RF, Microwave), Lab Devices (Mapping, Recording, ... Global Forecasts to 2019 ", published by MarketsandMarkets, the Electrophysiology ... by 2019 with a CAGR of around 10.3% during ... Browse   90   ma rket data T ...
(Date:3/27/2015)... 2015   Hospira, Inc. (NYSE: ... the world,s leading provider of injectable drugs and ... evaluation of biosimilarity of its proposed biosimilar, Epoetin ... (FDA) conditionally approved name of RETACRIT™, compared to ... study data were presented at the National Kidney ...
(Date:3/27/2015)... , March 27, 2015 ... 2015" therapeutic market research report of 52 pages ... online business intelligence library. The report ... on the therapeutic development for Visceral Pain, complete ... by drug target, mechanism of action (MoA), route ...
Breaking Medicine Technology:Electrophysiology (EP) Market Worth $4.73 Billion by 2019 2Electrophysiology (EP) Market Worth $4.73 Billion by 2019 3Electrophysiology (EP) Market Worth $4.73 Billion by 2019 4Hospira Clinical Data Shows Proposed Biosimilar, Epoetin Hospira, Demonstrates Pharmacokinetic And Pharmacodynamic Equivalence Compared To Amgen's Epogen 2Hospira Clinical Data Shows Proposed Biosimilar, Epoetin Hospira, Demonstrates Pharmacokinetic And Pharmacodynamic Equivalence Compared To Amgen's Epogen 3Visceral Pain Pipeline Review H1 2015 Market Research Report 2Visceral Pain Pipeline Review H1 2015 Market Research Report 3Visceral Pain Pipeline Review H1 2015 Market Research Report 4
... a world-leading developer and marketer of innovative medical technologies ... Ltd, a wholly-owned subsidiary of ConvaTec Holdings UK Ltd, ... a UK-based company that specialises in the discreet home ... As a well-respected company in the home ...
... President and CEO Randall Moreadith, MD, PhD, reported today that ... advance its lead oncology candidate SER-203 into a Phase I ... pleased to report to our existing and new shareholders the ... 2010. This is a very significant milestone for Serina Therapeutics, ...
Cached Medicine Technology:ConvaTec Announces Acquisition of Trent Direct 2Serina Therapeutics, Inc. Closes $9.5 Million Financing Round 2
(Date:3/28/2015)... 28, 2015 Designers and Professionals of ... entitled Scratches 5K from Pixel Film Studios. , “Scratches ... any media inside Final Cut Pro X” Said Christina ... time and is an effective tool for any FCPX ... Scratches 5K's intuitive grunge overlays. Simply drag title layers ...
(Date:3/28/2015)... CA (PRWEB) March 28, 2015 ... specialists , this week released a report about the ... symptoms of asthma sufferers, and according to recent medical ... , According to the Environmental Protection Agency, people ... asthmatic reactions. Breathing in mold may trigger asthma attacks ...
(Date:3/27/2015)... Island, NY (PRWEB) March 27, 2015 ... cancer-focused training and business criteria for the spa and ... services to clients who have experienced or are living ... the global Spafinder Wellness 365® Network, will be identified ... and recognized as a provider of safe, therapeutic services ...
(Date:3/27/2015)... The federal court overseeing thousands of ... medication increases the risk that a patient will develop ... Dismiss four individual cases that had been filed in ... in the U.S. District Court, District of South Carolina, ... were warranted because the plaintiffs in those claims had ...
(Date:3/27/2015)... March 27, 2015 Top medical tourism ... patients travel to the Dominican Republic to benefit from ... clinic is turning the medical tourism industry upside-down and ... — with trustworthy services becoming the central influence. ... plastic surgeon. Patients are not only attracted to low-cost ...
Breaking Medicine News(10 mins):Health News:Pixel Film Studios Unveiled Scratches 5k for Final Cut Pro X Editors 2Health News:Water Damage Restoration Specialists Servpro of Paso Robles Release Report on Mold and Asthma 2Health News:Water Damage Restoration Specialists Servpro of Paso Robles Release Report on Mold and Asthma 3Health News:Hands On HealthCare Massage Therapy & Wellness Day Spa Certified as “Cancer Aware” by Wellness for Cancer and Recognized on Spafinder.com 2Health News:Hands On HealthCare Massage Therapy & Wellness Day Spa Certified as “Cancer Aware” by Wellness for Cancer and Recognized on Spafinder.com 3Health News:Hands On HealthCare Massage Therapy & Wellness Day Spa Certified as “Cancer Aware” by Wellness for Cancer and Recognized on Spafinder.com 4Health News:Lipitor Lawsuits Move Forward in Federal Multidistrict Litigation, as Court Rules on Pfizer’s Motion to Dismiss Certain Cases 2Health News:Lipitor Lawsuits Move Forward in Federal Multidistrict Litigation, as Court Rules on Pfizer’s Motion to Dismiss Certain Cases 3Health News:Dominican Republic Plastic Surgery Provider Turning Medical Tourism Upside-Down 2Health News:Dominican Republic Plastic Surgery Provider Turning Medical Tourism Upside-Down 3
... many as 178 newborn babies died at a government-run ... Amar Agrawal told the state assembly Tuesday . ... about the lack of basic medical facilities at the ... reported 424 deaths of newly born babies in 2006 ...
... bird flu antibodies in migrant birds in five Siberian regions, ... ,"Out of over 4,000 samples taken in the ... to contain genetic material of the A-H5 virus and antibodies ... spokesman said the presence of antibodies meant that either the ...
... two studies indicate that elevated nonfasting triglyceride levels ... heart attack , with one study finding that ... this association. ,Triglyceride levels are usually ... certain types of lipoprotein particles (remnant lipoproteins), a ...
... patients a short course of corticosteroids after they have been ... of a relapse, a Cochrane Systematic Review has found. ... benefit lasts for about three weeks. ,This updated ... together involved 374 people. ,,Between 12% and 16% of ...
... is a more effective way of losing weight after pregnancy ... during pregnancy and many gradually lose it afterwards, but some ... retained body weight may be one factor that contributes to ... of returning to, and maintaining, pre-pregnant weights, and there is ...
... (saline) into your nose can help reduce the symptoms ... of the nasal passages. , ,Between 5% and ... passages (chronic rhinosinusitis). Many homoeopathic and yogic forms of ... symptoms, and it is now often recommended as part ...
Cached Medicine News:Health News:High Nonfasting Triglyceride Levels Linked With Cardiovascular Risks 2
1.0% Casein digest (NZ amine), 0.5% Sodium Chloride, 0.5% Yeast Extract, 1.0% bacto casamino acids, 0.2% Mag. Sulfate....
0.5% Yeast Extract, 2.0% Tryp, 10mM Sodium Chloride, 2.5mM Potassium Chloride, 10mM Magnesium Chloride, 10mM Mag. Sulfate....
Innovative hemi device combining anatomic design with the advanced material pyrocarbon....
3.2% Tryptone, 2.0% Yeast Extract, 0.5% Sodium Chloride, pH 7.5....
Medicine Products: